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Any Room for TAVR?*Antonio Colombo, MD, Azeem Latib, MDSEE PAGE 2330B icuspid aortic valve (BAV) disease is the mostcommon congenital cardiac defect, with aprevalence estimated between 0.5% and 2%
(1,2). The earliest description of BAV is attributed
to Leonardo da Vinci, who sketched the bicuspid
variant of the aortic valve over 400 years ago (3). In
the last 100 years, various authors have reported
the clinical sequelae of this common congenital dis-
ease, namely aortic stenosis or incompetence, en-
docarditis, aortic aneurysm formation, and aortic
dissection (1,2,4).
There are several variants of this valve anomaly.
Generally, BAV without any redundant tissue tends
to develop stenosis, whereas valves with more
redundant tissue usually develop valvular incompe-
tence (3). The incidence of aortic stenosis compli-
cating BAV in an autopsy series ranges from 15% to
75% (1). Progression of BAV stenosis is age related,
with ﬁbrosis beginning in the second decade and
calciﬁcation progressing signiﬁcantly after the fourth
decade. Among octogenarians and nonagenarians
undergoing surgical aortic valve replacement (AVR),
22% and 18%, respectively, were found to have BAV
(5). Bicuspid aortopathy (i.e., dilation of any or all
segments of the proximal aorta from the aortic root
to the aortic arch) is the most common nonvalvular
ﬁnding and is present in up to 50% of affected
persons (2,6). Abnormal dilation of the ascending
aorta is secondary to abnormalities of the aortic
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changes are present independent of whether the valve
is functionally normal, stenotic, or incompetent.
Ascending aorta pathology is an expression of the
genetic basis of BAV and may justify a more complex
surgical treatment (2).
All these differences between BAV and senile aortic
valve stenosis affecting tricuspid aortic valves may
justify the reason why BAV stenosis has been
considered a contraindication for transcatheter AVR
(TAVR) in most studies. The speciﬁc concerns
regarding TAVR for BAV include:
1. An elliptically shaped annulus that may impair
valve positioning and sealing.
2. Asymmetrical and heavy calciﬁcation of leaﬂets
may impede valve expansion and valve hemody-
namics (e.g., higher transvalvular gradients and
paravalvular leak).
3. Presence of aortic disease increases the risk of
dissection or rupture during valvuloplasty, post-
dilatation, or implantation of balloon-expandable
valves.
4. Fused commissures are susceptible to disruption
during balloon valvuloplasty, resulting in severe
aortic regurgitation.
5. Underexpansion and/or a non-circular shape of the
transcatheter heart valve may affect long-term
durability.Despite these concerns, we cannot dismiss the fact
that there are patients with severe aortic stenoses
who are not suitable surgical candidates and are
found to have BAV disease who would beneﬁt from
TAVR. However, until now, data regarding the feasi-
bility of TAVR in BAV have been limited to small case
series (7). The registry presented in this issue of the
Journal is the largest collection of patients treated
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2341with TAVR who have a BAV (8). The authors collected
data for 139 patients treated with TAVR in 12 centers
over 9 years. The diagnosis of BAV was established by
transesophageal echocardiography in all patients,
and in 63% of the patients, multislice computed
tomography (MSCT) also was performed. Despite
advanced multimodal imaging techniques, the diag-
nosis of BAV remained uncertain in 19 patients
(13.7%). The self-expandable transcatheter heart
valve (THV) (CoreValve, Medtronic Inc., Minneapolis,
Minnesota) was implanted in 91 patients (65%),
whereas the balloon-expandable THV (Sapien,
Edwards Lifesciences, Inc., Irvine, California) was
implanted in 48 patients. The procedures were per-
formed using transfemoral access in 78.5% of the
patients. There were no clinical differences between
the 2 groups of patients, except for a higher preva-
lence of atrial ﬁbrillation (30% vs. 15%, respectively)
in patients treated with the self-expandable valve.
Overall, this population should be considered at in-
termediate risk, with a Society of Thoracic Surgeons
predicted risk of mortality of 5%, whereas it was
11.8% in the PARTNER 1A (Placement of AoRTic
TraNscathetER Valve) trial (9) and 7.3% in the Core-
Valve pivotal trial (10). As expected, the mean diam-
eter of the valves used was 27.8 mm, which was
relatively large (valve diameters were 28.5 mm for the
self-expandable THV, where oversizing is less of an
issue). There was a need for a second valve in 4 versus
1 patient, who received balloon-expandable valve
implants. The procedural mortality was numerically
higher for the self-expandable THV (4.9% vs. 2.1%,
respectively; p ¼ 0.66), whereas the 1-year mortality
rate was lower for the self-expandable THV (12.5% vs.
20.8%, respectively; p ¼ 0.12). The 30-day incidence
of stroke was approximately 2%, with no differences
between the 2 valves. The procedure was effective in
most patients, with a 30-day combined efﬁcacy
endpoint achieved in 85% of the patients. The mean
aortic valve area increased from 0.6 cm2 to 1.7 cm2
when assessed by echocardiography at 30 days. Sig-
niﬁcant post-implantation aortic regurgitation
grade $2 was present in 28.4% of patients. Important
ﬁndings regarding this parameter are: 1) signiﬁcant
aortic regurgitation decreased to 17.4% when pre-
procedural annular assessment was performed by
MSCT; 2) signiﬁcant aortic regurgitation was 2 times
more frequent following implantation of the self-
expandable THV than the balloon-expandable THV
(32.2% vs. 19.6%, respectively; p ¼ 0.11); and 3) MSCT
evaluation was performed in 77.1% of patients who
received balloon-expandable valve implants versus
56% of patients treated with the self-expandable
valve (p ¼ 0.02). Interestingly, signiﬁcant aorticregurgitation was more frequent when the baseline
BAV anatomy was type 0 (no raphe, classic bicuspid
aortic valve).
The main conclusions we can draw from this
important study are:
1. TAVR with ﬁrst-generation aortic valves is feasible
in selected patients with BAV (device success of
90%, 1-year mortality of 17.5%, 30-day incidence
of stroke of 2%).
2. The incidence of signiﬁcant aortic regurgitation is
high at 28.4% (9% in the CoreValve pivotal trial
and 12.2% in the PARTNER 1A trial).
3. When accurate sizing is performed using MSCT, the
incidence of aortic regurgitation decreases to 17%.
4. The small number of patients and the fact thatMSCT
was more frequently used with the balloon-
expandable valve than with the self-expandable
valve does not allow us to make hypotheses
regarding the most suitable ﬁrst-generation valve
for BAV.
IMPACT OF THIS STUDY ON TAVR
Unless next-generation transcatheter valves show
better performance regarding prevention of residual
aortic regurgitation, the incidence of signiﬁcant aortic
regurgitation following ﬁrst-generation transcatheter
valves implantation, even with full MSCT evaluation,
is too high to extend TAVR to BAV unless the patient is
truly inoperable or has an unacceptably high surgical
risk. However, the current study does set a benchmark
for next-generation TAVR devices and does demon-
strate the feasibility of TAVR in BAV. The presence of
signiﬁcant aortic root dilation, not present in this
study, probably demands complete surgical correc-
tion rather than TAVR, and a question mark remains
regarding TAVR when aortic regurgitation is the main
defect. The results presented reinforce the suggestion
that BAV is predominantly a disease of the “young
patient” and thus remains in the surgical domain.
Nevertheless, we cannot dismiss the fact that
approximately 20% of elderly patients with critical
aortic stenosis have BAV and that it is in these high-
risk elderly patients where the role of TAVR needs to
be clearly deﬁned. To conclude, we can state that the
study presented in this issue of the Journal gives us a
realistic perspective of TAVR in BAV and deﬁnes areas
of improvement if the goal is to continue to treat more
patients in a less invasive way.
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